Luc Van Gaal, MD

Luc Van Gaal, MD

Professor of Medicine
Department of Endocrinology, Diabetology and Metabolism
Antwerp University Hospital
Antwerp, Belgium

Related Videos

Are there next-generation GLP-1 RAs in development? How are they similar and how might they differ from currently available agents? Dosing-wise? Efficacy? Side effects? Weight loss? Video

Are there next-generation GLP-1 RAs in development? How are they similar and how might they differ from currently available agents? Dosing-wise? Efficacy? Side effects? Weight loss?

Are there next-generation GLP-1 RAs in development? How are they similar and how might they differ from currently available agents? Dosing-wise? Efficacy? Side effects? Weight loss?

In what ways do you believe the fixed-ratio combinations of insulin plus a GLP-1 RA will help overcome the barriers we have seen with intensifying insulin or GLP-RA therapy? Video

In what ways do you believe the fixed-ratio combinations of insulin plus a GLP-1 RA will help overcome the barriers we have seen with intensifying insulin or GLP-RA therapy?

In what ways do you believe the fixed-ratio combinations of insulin plus a GLP-1 RA will help overcome the barriers we have seen with intensifying insulin or GLP-RA therapy?

What is the relationship between between GLP-1 RA and body weight? What did we learn about liraglutide, dosing regimens, and body weight -- specifically weight loss -- from LEADER and other trials? Video

What is the relationship between between GLP-1 RA and body weight? What did we learn about liraglutide, dosing regimens, and body weight -- specifically weight loss -- from LEADER and other trials?

What is the relationship between between GLP-1 RA and body weight? What did we learn about liraglutide, dosing regimens, and body weight — specifically weight loss — from LEADER and other trials?

Why do you believe the results of LEADER, showing CV outcome reduction with liraglutide, are different from previous trials using GLP-1 RAs that failed to demonstrate CV risk reduction? Video

Why do you believe the results of LEADER, showing CV outcome reduction with liraglutide, are different from previous trials using GLP-1 RAs that failed to demonstrate CV risk reduction?

Why do you believe the positive results of the LEADER trial, showing CV outcome reduction with liraglutide, are different from previous trials using other GLP-1 RAs that failed to demonstrate CV risk reduction?

How do the fixed-ratio insulin formulations mitigate the side effects associated with either insulin alone or a GLP-1 RA given alone? Video

How do the fixed-ratio insulin formulations mitigate the side effects associated with either insulin alone or a GLP-1 RA given alone?

How do the fixed-ratio insulin formulations mitigate the side effects associated with either insulin alone or a GLP-1 RA given alone?

What is the physiologic and mechanistic rationale for using a fixed-ratio combination insulin plus GLP-1 receptor agonist such as iDegLira and iGlarLixi as part of the treatment landscape? Video

What is the physiologic and mechanistic rationale for using a fixed-ratio combination insulin plus GLP-1 receptor agonist such as iDegLira and iGlarLixi as part of the treatment landscape?

What is the physiologic and mechanistic rationale for using a fixed-ratio combination insulin plus GLP-1 receptor agonist such as iDegLira and iGlarLixi that are or will be part of the treatment landscape?

Given the modest reductions in such CV risk factors as BP and weight, what might be the mechanistic effects that explain the significant reduction in CV outcomes observed in LEADER? Video

Given the modest reductions in such CV risk factors as BP and weight, what might be the mechanistic effects that explain the significant reduction in CV outcomes observed in LEADER?

Given the rather modest reductions in such CV risk factors as BP and weight, what do you believe might be the mechanistic or physiologic effects that explain the significant reduction in CV outcomes observed in LEADER?

What were the specific clinical and CV risk profiles of the patients studied in LEADER? And how will this help us identify patients who might benefit from liraglutide? Video

What were the specific clinical and CV risk profiles of the patients studied in LEADER? And how will this help us identify patients who might benefit from liraglutide?

What were the specific clinical and CV risk profiles of the patients studied in LEADER? And how will this help us identify patients who might benefit from liraglutide?

As an investigator for LEADER, what features of this study with respect to CV and mortality outcomes deserve special emphasis? How do they differ from other CV outcome trials in diabetes? Video

As an investigator for LEADER, what features of this study with respect to CV and mortality outcomes deserve special emphasis? How do they differ from other CV outcome trials in diabetes?

As an investigator for LEADER, what features of this study with respect to CV and mortality outcomes deserve special emphasis? How do they differ from other CV outcome trials in diabetes?